focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCreo Medical Regulatory News (CREO)

Share Price Information for Creo Medical (CREO)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 35.65
Bid: 35.30
Ask: 36.00
Change: 2.30 (6.97%)
Spread: 0.70 (1.983%)
Open: 32.70
High: 35.30
Low: 35.30
Prev. Close: 33.00
CREO Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

CTO wins Technology Innovator of the Year Award

5 Apr 2022 07:00

RNS Number : 2295H
Creo Medical Group PLC
05 April 2022
 

REACH

Creo Medical Group plc

("Creo" the "Company" or the "Group")

 

Creo CTO & Founder wins inaugural Technology Innovator of the Year Award at European Microwave Week

 

Chris Hancock wins $25,000 prize for first advanced energy multimodality instrument designed for flexible endoscopy using combined bipolar RF and microwave energy for advanced endoscopic procedures

 

Creo Medical Group plc (AIM: CREO), a medical device company focused on the emerging field of surgical endoscopy, announces that its Chief Technology Officer (CTO) and Founder, Chris Hancock, has won an inaugural Technology Innovator of the Year Award at European Microwave Week.

 

The ceremony, sponsored by Junkosha, the pioneers of sophisticated fluoropolymer application technologies across Interventional Medical and Microwave and Millimeter Wave sectors, took place yesterday in London, UK, and saw Chairperson of the Awards, Joe Rowan, present Chris with the Award and the $25,000 prize.

 

Junkosha launched its Technology Innovator of the Year Award in March 2021 as part of a celebration of milestones including its new corporate image and website. The Award was designed to recognise the innovative work of an individual or team working in the delivery of products used within Interventional Medical procedures or Microwave/Millimeter Wave technologies. Its aim was to highlight the achievements of pioneers in advanced technology together with their contributions to society. Chris Hancock and Creo Medical were selected by a distinguished panel of judges following presentations completed by a shortlist of five candidates throughout February.

Chris Hancock is the founder and Chief Technology Officer of Creo Medical, with over 20 years' experience in medical device development including four years at Gyrus Group plc in his role as Senior Engineer. Chris holds a personal Chair in the Medical Microwave Systems Research Group at Bangor University and is a Fellow of the Institute of Physics, a Chartered Physicist, a Fellow of the Institute of Engineering and Technology, a Chartered Engineer and a Senior Member of the IEEE. 

Joe Rowan, Chairperson for the Award, and Junkosha's President and CEO of USA and Europe, explained: "We are very excited and proud to present Creo Medical and Chris Hancock as our first Technology Innovator of the Year Award winner. Chris' breakthrough technology holds the potential to transform the point of treatments for a range of cancers. Overall, Chris' achievement is one we can use as a yardstick to measure others in future years."

Mamoru Sogo, President and CEO of Junkosha Inc, said: "We believe that enabling innovators, like Creo Medical, is central to the philosophy behind the Junkosha brand as we continually look to advance the next generation of technology for a better future. As part of the plans to raise awareness of our new brand internationally, the Awards program delivers a tangible commitment to our values. We congratulate Chris Hancock and Creo Medical on their Award and look forward to observing their continued success well into the future."

Chris Hancock, Chief Technology Officer of Creo, commented: "I was delighted to be nominated for this accolade, even more to win it and have the work we are doing at Creo Medical recognised in this way. It is a real honour.

"Like most innovations - our products and the technology that powers them are all products of an idea. From the beginning in 2001 our idea has always been about harnessing advances in technology, together with creative and innovative thinking, to help patients and to offer a better alternative for treating cancer as well as other indications. I have been fortunate enough to see that belief materialise into something that is transforming lives every day, and which has the real potential to move the needle in how all manner of surgical procedures are conducted.

"I look forward to ensuring that this $25k prize is used to empower and encourage others with an idea or a passion to see it reach its potential. As we've said many times at Creo - anything is possible with the right approach."

 

For more information about our Technology Innovation of the Year Awards, click here: https://www.junkosha.com/en/news/54.

 

Enquiries:

 

Creo Medical Group plc

www.creomedical.com

Richard Rees (CFO)

+44 (0)1291 606 005

 

 

Cenkos Securities plc

+44 (0)20 7397 8900

Stephen Keys / Camilla Hume (NOMAD)

 

Michael Johnson / Russell Kerr (Sales)

 

 

 

Numis Securities Limited (Joint Broker)

Freddie Barnfield / James Black / Duncan Monteith

+44 (0)20 7260 1000

 

 

Walbrook PR Ltd

Tel: +44 (0)20 7933 8780 or creo@walbrookpr.com

Paul McManus / Sam Allen /

Phillip Marriage

Mob: +44 (0)7980 541 893 / +44 (0)7502 558 258 / +44 (0)7867 984 082

 

 

About Creo Medical

 

Creo Medical is a medical device company focused on the development and commercialisation of minimally invasive electrosurgical devices, bringing advanced energy to endoscopy.

 

The Company's vision is to improve patient outcomes through the development and commercialisation of a suite of electrosurgical medical devices, each enabled by CROMA, powered by Kamaptive. The Group has developed the CROMA powered by Kamaptive full-spectrum adaptive technology to optimise surgical capability and patient outcomes. Kamaptive is a seamless, intuitive integration of multi-modal energy sources, optimised to dynamically adapt to patient tissue during procedures such as resection, dissection, coagulation and ablation of tissue. Kamaptive technology provides clinicians with increased flexibility, precision and controlled surgical solutions. CROMA currently delivers bipolar radiofrequency ("RF") energy for precise localised cutting and focused high frequency microwave ("MW") energy for controlled coagulation and ablation via a single accessory port. This technology, combined with the Group's range of patented electrosurgical devices, is designed to provide clinicians with flexible, accurate and controlled clinical solutions. The Directors believe the Company's technology can impact the landscape of surgery and endoscopy by providing a safer, less-invasive and more cost-efficient option for procedures.

 

For more information, please refer to the website www.creomedical.com

 

About Junkosha 

Junkosha are pioneers of sophisticated fluoropolymer application technologies across medical device and microwave interconnect sectors. With three operations in Japan, including its headquarters as well as sites in the US, UK and China, it is one of the best kept advanced technology secrets outside of Japan. The company provides tube and fitting products, including generic resin tubes, fluoropolymer tubes, high-barrier tubes, flexible multi-layered tubes, industrial hoses, degassing modules, heat-shrinkable tubes, and the market leading peelable heat shrink tubes. It also provides wire and cable products, including microwave interconnects, robot cables, high data rate cables, camera link cable assemblies, ultrafine coaxial cables and assemblies, cables for clean environments, and general wires and cables.

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NRABCGDSRSGDGDS
Date   Source Headline
26th Apr 20107:00 amRNSUpdate on Proposed Asian Listing
26th Mar 20104:35 pmRNSShareholder notification
25th Mar 20103:10 pmRNSSale of CREO shares
25th Mar 20107:00 amRNSDirector/PDMR Shareholding
23rd Mar 20107:00 amRNSResult of Tender Offer
8th Mar 20107:00 amRNSCircular re Tender Offer
8th Mar 20107:00 amRNSPreliminary Results
19th Feb 20107:00 amRNSBlocklisting Interim Review
5th Feb 20107:00 amRNSTrading Update
18th Jan 20107:00 amRNSDisposal
10th Dec 20097:00 amRNSNew Loan Facility
30th Nov 20094:13 pmRNSDirector Disclosure
25th Nov 20095:34 pmRNSDirector Declaration
25th Nov 200912:00 pmRNSProposed issue of zero dividend preference shares
20th Nov 20099:49 amRNSDisposal
12th Nov 20099:48 amRNSDisposal
5th Nov 200910:12 amRNSDisposal
7th Sep 200910:39 amRNSPublication of Financial Accounts
25th Aug 20097:00 amRNSInterim Results
18th Aug 20097:00 amRNSDirectorate Change
4th Aug 20097:00 amRNSTreasury Building Refinance
6th Jul 20097:00 amRNSBlocklisting Interim Review
1st Jul 20097:00 amRNSDirector/PDMR Shareholding
29th Jun 20097:00 amRNSDirectorate Change
24th Jun 20097:00 amRNSDisposal of Minority Stake
11th Jun 20097:00 amRNSAmendments to Investment Management Agreement
10th Jun 200911:18 amRNSResult of AGM
23rd Apr 200910:34 amRNSAnnual Report and Accounts
20th Apr 200912:52 pmRNSHolding(s) in Company
9th Apr 20099:05 amRNSIssue of Equity
3rd Apr 20091:24 pmRNSNotifiable interest in securities
1st Apr 20093:20 pmRNSDirector/PDMR Shareholding
23rd Mar 20093:24 pmRNSDirector/PDMR Shareholding
19th Mar 20097:00 amRNSFinal Results
22nd Jan 20095:00 pmRNSDirector/PDMR Shareholding
20th Jan 200911:00 amRNSSignificant shareholder notification
16th Jan 20099:31 amRNSTransaction in Own Shares
15th Jan 20093:57 pmRNSNotifiable interest in securities
15th Jan 20098:46 amRNSTransaction in Own Shares
13th Jan 20099:00 amRNSRe Call Option Agreement
5th Jan 20093:40 pmRNSSignificant shareholder notification
5th Jan 200910:39 amRNSSignificant shareholder notification
2nd Jan 20099:34 amRNSBlock Listing 6 monthly review
31st Dec 20089:57 amRNSTransaction in own securities
19th Dec 20084:33 pmRNSTransaction in Own Shares
9th Dec 20087:00 amRNSAppointment of Nomad and Joint Broker
8th Dec 20084:14 pmRNSGrant of Options
3rd Dec 200811:25 amRNSResult of EGM
26th Nov 20087:00 amRNSAppointment of Joint Broker
26th Nov 20087:00 amRNSRREEF Share Purchase

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.